timber pharmaceuticals llc, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. the company was founded in 2019 and is based in woodcliff lake, new jersey.
Company profile
Ticker
TMBR
Exchange
Website
CEO
John Koconis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioPharmX Corp, THOMPSON DESIGNS INC
SEC CIK
Corporate docs
Subsidiaries
BioPharmX, Inc. • Timber Pharmaceuticals Australia Pty Ltd. • Timber Pharmaceuticals LLC ...
IRS number
593843182
TMBR stock data
Latest filings (excl ownership)
8-K
Other Events
26 Mar 24
8-K
Other Events
21 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
26 Jan 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Other Events
22 Dec 23
25-NSE
Exchange delisting
29 Nov 23
8-K
In the United States Bankruptcy Court for the District of Delaware
28 Nov 23
8-K
Entry into a Material Definitive Agreement
17 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
17 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Jan 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.52 mm | 2.52 mm | 2.52 mm | 2.52 mm | 2.52 mm | 2.52 mm |
Cash burn (monthly) | 885.33 k | 479.52 k | 1.33 mm | 1.22 mm | 885.33 k | 1.16 mm |
Cash used (since last report) | 8.71 mm | 4.72 mm | 13.11 mm | 12.05 mm | 8.71 mm | 11.38 mm |
Cash remaining | -6.19 mm | -2.20 mm | -10.59 mm | -9.53 mm | -6.19 mm | -8.86 mm |
Runway (months of cash) | -7.0 | -4.6 | -7.9 | -7.8 | -7.0 | -7.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 270.65 mm |
Total shares | 9.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 5.76 mm | $553.00 k |
TardiMed Sciences | 3.31 mm | $3.19 mm |
Vanguard | 38.69 k | $94.01 mm |
Citadel Advisors | 33.19 k | $80.64 mm |
Geode Capital Management | 19.80 k | $48.11 mm |
STT State Street | 14.44 k | $35.09 mm |
Tower Research Capital | 2.92 k | $7.11 mm |
UBS UBS Group AG - Registered Shares | 800.00 | $1.94 mm |
Steward Partners Investment Advisory | 1.00 | $2.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Aug 23 | Joseph Lucchese | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 35,193 | 0.00 | 35,193 |
20 Aug 23 | Alan Mendelsohn | Common Stock, par value $0.001 per share | Grant | Acquire A | No | No | 0 | 35,193 | 0.00 | 35,393 |
20 Aug 23 | John Koconis | Common Stock, par value $0.001 per share | Grant | Acquire A | No | No | 0 | 70,385 | 0.00 | 70,785 |
15 Apr 23 | Joseph Lucchese | Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 22,505 | 37.36 k | 22,505 |
15 Apr 23 | Cohen David E | Common Stock, par value $0.001 per share | Grant | Acquire A | No | No | 0 | 4,100 | 0.00 | 6,100 |
15 Apr 23 | Cohen David E | Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 4,100 | 6.81 k | 4,100 |